Larimar Therapeutics Inc 2026年季度报告

Form 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___ to ____Commission File Number: 001-36510 LARIMAR THERAPEUTICS, INC. 20-3857670(I.R.S. EmployerIdentification No.)19004(Zip Code) (844) 511-9056(Registrant’s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of August 2, 2026, there were 103,882,937 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements made in this Quarterly Report on Form 10-Q that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements discuss our business, operations and financial performance and conditions, as well as our plans, objectives andexpectations for our business operations and financial performance and condition. In some cases, you can identify forward-lookingstatements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,”“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,”“will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative ofthese terms or other comparable terminology. In addition, statements that “we believe” or similar statements reflect our beliefs andopinions on the relevant subject only. These forward-looking statements, which are subject to risks, uncertainties and assumptionsabout us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends inour business. You should understand that the following important factors could affect our future results and could cause those results orother outcomes to differ materially from those expressed or implied in our forward-looking statements: •uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety,tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (“FDA”), EuropeanMedicines Agency (“EMA”) and other comparable regulatory authorities for marketing approval for nomlabofusp orany other product candidates that we may develop in the future and unexpected costs that may result therefrom; •delays in patient recruitment for our clinical trials (including as a result of the impact of FDA approval of competitiveproducts for the treatment of Friedreich's ataxia (“FA”), and/or the impact of other clinical trials of competitiveproducts), delays as a result of clinical and non-clinical results and/or the FDA's request for additional information orstudies (whether clinical or non-clinical), changes in clinical protocols, adverse events, regulatory restrictions, includingclinical holds, and milestones for nomlabofusp;•our ability to successfully execute our ongoing open label trial and our planned Phase 3 global registration study,including the timing of site initiations and the rate of patient enrollment;•our ability to benefit from participating in the FDA’s Support fo